A psychostimulant and entactogenic designer drug similar to aminorex, 4-methylaminorex, and pemoline is 4,4′-Dimethylaminorex (abbreviated as 4,4′-DMAR), often referred to by the street name “Serotoni”. It was first detected in the Netherlands in December 2012, and since mid-2013 has been marketed across Europe as a designer drug.
By February 2014, 4,4′-DMAR had been linked to at least 31 fatalities in Hungary, Poland, and the UK, often when used in conjunction with other medications. In Northern Ireland, nineteen deaths related to 4,4′-DMAR were recorded in the same time span.
4,4′-DMAR serves as a potent and balanced releasing agent for serotonin-norepinephrine-dopamine (SNDRA) with EC50 values of 18,5 nM, 26,9 nM and 8,6 nM respectively for serotonin, norepinephrine and dopamine release.